This article is best viewed in a PDF Format.
A key development within the management of retinal disease has been the introduction of drug delivery directly into the posterior chamber of the eye. While there has been significant commentary on the use of agents such as Lucentis for wet macular generation, there is also a continuing focus on drug delivery for treatment of macular oedema as a result of other conditions, for example retinal vein occlusion.1 Such agents work by entering cells and blocking the production of vascular endothelial growth factor (VEGF) and prostaglandins, substances that are involved in inflammation and swelling.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here